*To the Editor*:

We read with interest the observational findings of Han and colleagues, who reported that raised serum estradiol was associated with a lower likelihood of asthma in obese women and in nonobese men ([@bib1]). Pointedly, their study did not evaluate the potential effect of progesterone, which is known to aggravate airway IL-5--mediated eosinophilia and associated airway hyperresponsiveness to methacholine in the murine model of allergic asthma ([@bib2]). Moreover, increased endogenous luteal phase progesterone levels in women with asthma are accompanied by a marked increase in airway hyperresponsiveness to adenosine monophosphate, which can be abolished by the combined oral contraceptive pill ([@bib3]). Interestingly, in women with asthma, exogenous progesterone, but not estradiol, results in downregulation of lymphocyte β-2 receptors and an attenuated 3′,5′-cyclic adenosine monophosphate response to isoproterenol ([@bib4]), whereas in women without asthma, the opposite occurs ([@bib5]), and in men without asthma, there is no change ([@bib6]). Hence, we believe that further observational-type studies should also focus on cyclical changes in sex hormones, including progesterone, in women, as this is more likely to explain sex-specific differences in asthma.
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